ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II randomized, controlled, open label breast cancer clinical trial. 66
patients will be enrolled. The drugs being studied are hydroxychloroquine (Plaquenil) and
abemaciclib (also Verzenio). This research study is testing whether using these drugs to
target the disseminated tumor cells in bone marrow can reduce their number or eliminate them.
Both hydroxychloroquine and abemaciclib are pills that will be taken twice daily. Both are
approved by the FDA
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania